@article{oai:shiga-med.repo.nii.ac.jp:00000080,
 author = {花岡, 淳 and HANAOKA, Jun and 紺谷, 桂一 and KONTANI, Keiichi and 澤井, 聡 and SAWAI, Satoru and 藤野, 昇三 and FUJINO, Shozo and 大久保, 岩男 and OHKUBO, Iwao},
 journal = {滋賀医科大学雑誌},
 month = {Feb},
 note = {MUC4 mucin, which was cloned from human tracheo-bronchial mucosa cDNA library, has been reported to be abundantly expressed in lung cancer. Although expression levels of MUC4 mRNA in several cancer cells have been examined, biological characteristics of MUC4 protein have not been investigated becauseof no available antibodies for this mucin. In this study, we prepared antisera from rabbits immunized with MUC4 core peptides synthesized according to the sequences of the MUC4 tandem repeat. Despite of its high hydrophobicity and beta-sheet structures, the obtained antisera showed specific reactivities with MUC4 core. Lung cancer tissues from 27 cancer patients were examined for MUC4 protein expression byan immunohistochemical study using the antisera. Sixty-seven % of the tumors were demonstrated to express MUC4 protein. MUC4 mRNA expressions in the cancer tissues were examined by Northern hybridization using oligonucleotide probes whose sequences were corresponding to those of the MUC4 tandem repeat.Seventy-two % of the tumors showed high levels of MUC4 mRNA expression. Overall, the MUC4 protein expression was elevated in lung cancer tissues because of the increase in its mRNA expression and deglycosylation on its core. There was no correlation between clinical factors of the patients and their MUC4 expression. These data suggest that MUC4 mucin is abundantly expressed in lung cancer cells and that antigenicdeterminants sufficiently immunogenic to elicit anti-MUC4 immunity exist within the MUC4 tandem repeat. MUC4 is expected to be useful as a target antigen in immunotherapy for lung cancer.},
 pages = {17--26},
 title = {肺癌におけるMUC4ムチン発現の解析},
 volume = {16},
 year = {2001},
 yomi = {ハナオカ, ジュン and コンタニ, ケイイチ and サワイ, サトル and フジノ, ショウゾウ and オオクボ, イワオ}
}